Regeneron Pharmaceuticals Cash Flow Statement
REGN / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Regeneron Pharmaceuticals generated $5.0B in operating cash flow and $4.1B in free cash flow in FY2025. Free cash flow margin was 28.4% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $4.5B | $4.4B | $4.0B | $3.5B | $2.1B | $2.4B | $2.1B | $2.4B | $1.2B | $895.5M | $636.1M | $338.1M | -$221.8M | $750.3M | -$67.8M |
| Depreciation & Amortization | $543.7M | $482.9M | $421.0M | $235.9M | $210.3M | $148.2M | $210.3M | $148.2M | $145.5M | $104.7M | $74.9M | $52.7M | $31.1M | $36.9M | $14.2M |
| Operating Cash Flow | $5.0B | $4.4B | $4.6B | $2.6B | $2.4B | $2.2B | $2.4B | $2.2B | $1.3B | $1.5B | $1.3B | $752.4M | -$141.7M | -$74.6M | -$69.9M |
| Capital Expenditures | $898.4M | $755.9M | $718.6M | $614.6M | $429.6M | $383.1M | $429.6M | $383.1M | $272.6M | $511.9M | $677.9M | $333.0M | $57.2M | $49.3M | $97.3M |
| Free Cash Flow | $4.1B | $3.7B | $3.9B | $2.0B | $2.0B | $1.8B | $2.0B | $1.8B | $1.0B | $974.0M | $652.8M | $419.4M | -$198.9M | -$124.0M | -$167.3M |
| Share Buybacks | $3.4B | $2.6B | $2.2B | $5.8B | $275.9M | $4.4M | $275.9M | $4.4M | $0 | $0 | - | - | - | - | - |
| Dividends Paid | $370.3M | $0 | $0 | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Margin | 28.4% | 25.8% | 29.5% | 23.6% | 30.5% | 35.2% | 30.5% | 35.2% | 78.4% | 20.0% | 15.9% | 14.9% | -44.6% | -9.0% | -44.1% |